Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Empagliflozin
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Recipient : Boehringer Ingelheim GmbH
Deal Size : Undisclosed
Deal Type : Acquisition
Torrent Pharma Inks Agreement with Boehringer Ingelheim to Acquire 3 Anti-Diabetes Brands
Details : The acquisition strengthens Torrent’s existing diabetes portfolio by adding Cospiaq (empagliflozin), Cospiaq Met (empagliflozin & metformin) and Xilingio (empagliflozin & linagliptin) from Boehringer.
Product Name : Cospiaq
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 04, 2024
Lead Product(s) : Empagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Recipient : Boehringer Ingelheim GmbH
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Dichlorphenamide
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Recipient : Cycle Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
New U.S. Product ORMALVI Tablets Launches for Primary Periodic Paralysis Treatment
Details : Ormalvi (dichlorphenamide) is a carbonic anhydrase inhibitor. The generic version has been approved and is indicated for the treatment of primary hyperkalemic periodic paralysis and related variants.
Product Name : Ormalvi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 05, 2024
Lead Product(s) : Dichlorphenamide
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Recipient : Cycle Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tiopronin
Therapeutic Area : Nephrology
Study Phase : Approved FDF
Recipient : Cycle Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
New Tiopronin Delayed-Release Tablets Launch For Cystinuria Treatment
Details : Tiopronin is an active reducing agent which undergoes thiol-disulfide exchange with cystine to form a mixed disulfide of tiopronin-cysteine. It is indicated for cystinuria.
Product Name : Tiopronin-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 13, 2024
Lead Product(s) : Tiopronin
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Recipient : Cycle Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dichlorphenamide
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dichlorphenamide is a carbonic anhydrase inhibitor. The generic version has been approved and is indicated for the treatment of primary hyperkalemic periodic paralysis and related variants.
Product Name : Keveyis-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 04, 2023
Lead Product(s) : Dichlorphenamide
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TRC041266
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 11, 2020
Lead Product(s) : TRC041266
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dapsone
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Catawba Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 11, 2019
Lead Product(s) : Dapsone
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Catawba Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nebivolol
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 07, 2018
Lead Product(s) : Nebivolol
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nebivolol
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 07, 2018
Lead Product(s) : Nebivolol
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olmesartan Medoxomil
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 24, 2017
Lead Product(s) : Olmesartan Medoxomil
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olmesartan Medoxomil
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 23, 2017
Lead Product(s) : Olmesartan Medoxomil
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
